Here are four facts on biosimilars:
1. The market is likely to hit $30 billion in 2020.
2. Between 2014 and 2020, analysts expect the biosimilars market to increase at a 62.1 percent compound annual growth rate.
3. Europe will dominate the market over the next five year to seven years due to pricing mechanisms, physician awareness and regulations.
4. Some of the market’s primary companies include Novartis, Lonza, Boehringer Ingelheim, Amgen, Sandoz, Pfizer, Mylan, Samsung Bioepis, Hospira and Eli Lilly.
More articles on quality and infection control:
Reducing ventilator-associated events — 3 study insights
UCLA researchers detect antibiotic-resistant superbugs in 4 California parks
Life expectancy varies by US county: 5 study findings
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
